336 results
Page 10 of 17
6-K
EX-99.1
w0w08c
10 Oct 12
New Data Presented at the 28TH Ectrims Congress Showcase Teva’s Ongoing Commitment to Multiple Sclerosis Research
12:00am
6-K
EX-99.1
x3rsvz0s 6o
27 Sep 12
Drug candidate to be assessed for managing voluntary motor disturbances in Huntington disease
12:00am
6-K
EX-99.99
9n50owx9 327
13 Sep 12
Live Filing
12:00am
6-K
EX-99.1
g6zk9nevlqvcs
30 Aug 12
Teva Announces Fda Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-induced Neutropenia
12:00am
6-K
EX-99.1
q2uf64w1
17 Aug 12
Teva Announces Launch of Generic Actos® in the United States
12:00am
6-K
EX-99.1
d56s1aalxfox1zi
17 Aug 12
Teva Announces Launch of Generic ACTOplusmet® in the United States
12:00am
6-K
EX-99.1
prfg659p e5aih9
8 Aug 12
Teva to Initiate Third Phase Iii Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
12:00am
6-K
EX-99.1
os757
6 Aug 12
Teva Reports Second Quarter 2012 Results
12:00am
6-K
0mimg4i7t i8
2 Aug 12
Current report (foreign)
12:00am
6-K
EX-99.1
zt0561te o5ff
2 Jul 12
Teva Announces Progress of Biologic Investigational Drugs Evaluated to Treat Neutropenia In Breast Cancer Patients Undergoing Chemotherapy
12:00am
6-K
EX-99.1
oykosj
21 Jun 12
Teva Announces Launch of Generic Symbyax® in the United States
12:00am
6-K
EX-99.1
d02e x48dz1
19 Jun 12
Live Filing
12:00am
6-K
EX-99.1
wihxp
19 Jun 12
More Than 15 Clinical, Pre-Clinical and Health Economics Studies Will Be Presented
12:00am
6-K
EX-99.1
oifu4a
1 Jun 12
Teva Pharmaceutical Industries Ltd. Chairman of the Board Dr. Phillip Frost Purchases 1 Million Teva Shares
12:00am
6-K
EX-99.1
82uh9
24 May 12
Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
12:00am
6-K
EX-99.1
gs2ya97fq28dv
23 May 12
Live Filing
12:00am
6-K
EX-99.1
z8svm r34en0ebbr
17 May 12
Teva’s Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board
12:00am
6-K
3bgq 23ifc698
9 May 12
Current report (foreign)
12:00am
6-K
7xc emm1y7p
9 May 12
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
EX-99.1
f4mhu9 7uh50cp9
8 May 12
Teva Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer
12:00am